A new study published in Veterinary Medicine and Science suggests that a carefully chosen pair of feed enzymes can dismantle many of those barriers. Researchers set out to determine whether phytase, protease, or the two together could alleviate the digestive limitations imposed by canola seed in broiler chickens, with a practical eye on which single enzyme delivers the most value when budgets allow only one. The question matters commercially: with protein-rich feed ingredients fluctuating wildly in price, industry stakeholders want to know exactly where their enzyme dollars are best spent.

The experiment involved 300 one-day-old male Ross 308 chicks, distributed in a completely randomised design across five treatments with five replicates of twelve birds each. One group received a corn-soybean meal control diet with no canola seed. A second received a diet containing 10 percent canola seed without enzymes. The remaining three groups ate the canola-seed diet supplemented with protease, with phytase, or with both enzymes together. Protease was included at 0.15 grams per kilogram of feed and phytase at 0.05 grams per kilogram. Birds were raised through starter, grower and finisher phases spanning 42 days, with feed and water available freely and standard vaccination protocols against Newcastle disease and infectious bursal disease applied.

The canola seed itself was thoroughly characterised before the trial began. Analysis showed 21.25 percent crude protein, a striking 42.76 percent ether extract, 18.39 percent crude fibre, and a gross energy content of 7063 kilocalories per kilogram. The seed also contained 5264 milligrams per kilogram of phytate phosphorus, 0.36 percent tannins and 9.37 micromoles per gram of glucosinolates, the very compounds suspected of constraining bird performance. Diets were formulated to be nutritionally comparable across treatments, with the canola diets naturally higher in fat and linoleic acid owing to the oil-rich seed.

The performance results told a clear story. Birds fed the unsupplemented canola diet ate significantly less, gaining roughly 6 to 7 grams less feed per day during the starter phase than controls, and their body weight gain suffered accordingly across the starter, grower and overall periods. Feed conversion ratio was also worse in the canola group during the grower phase. But adding enzymes changed the picture. Protease alone improved weight gain and feed intake relative to the canola-only diet, though its effect on intake was modest. Phytase alone produced a more pronounced lift in feed intake. The combination of both enzymes, however, was the standout: birds on the dual-enzyme diet ate and grew at rates statistically indistinguishable from the soybean-fed controls, effectively erasing the canola penalty.

Digestibility data revealed why. Apparent metabolisable energy, which fell to around 2687 kilocalories per kilogram in the canola-only group, rebounded to control levels of roughly 2860 kilocalories per kilogram in the phytase and combination groups. Crude protein digestibility told an equally interesting tale: the protease and combination diets actually exceeded the control diet, reaching about 74 to 75 percent digestibility compared with 71.7 percent in the soybean control. Ash and crude fibre digestibility were also restored by phytase-containing treatments. In other words, the enzymes did not merely compensate for canola’s drawbacks; in the case of protein digestion, they pushed nutrient utilisation beyond what the conventional soybean diet achieved.

The physiological mechanisms behind these gains emerged from a battery of measurements on the birds’ digestive systems. At 10 days of age, when the endogenous enzyme system is still immature, activities of amylase, lipase and total protease in the jejunum were depressed in the canola-only group but elevated in all enzyme-supplemented groups, with the combination treatment producing the highest amylase and lipase values. By day 42, when the birds’ own digestive machinery had matured, these differences had disappeared, underscoring that exogenous enzymes matter most in early life. Jejunal morphology followed a similar pattern: villus height and the villus-height-to-crypt-depth ratio, key indicators of absorptive capacity, were significantly higher in phytase and combination groups, while the canola-only diet drove deeper crypts, a sign of increased epithelial turnover under intestinal stress.

The gut microbiota and the physical properties of the intestinal contents added further layers of explanation. At day 10, birds on the combination diet harboured the highest Lactobacillus populations and the lowest Escherichia coli counts in the ileum, while Clostridium perfringens was lowest in that group compared with the canola-only treatment. Intestinal digesta viscosity, a critical determinant of how easily nutrients diffuse to digestive enzymes, was significantly elevated in the duodenum and jejunum of canola-fed birds but reduced by enzyme supplementation, particularly in the ileum. The researchers attribute this to phytase disrupting viscous phytate-protein complexes and protease breaking down peptide-fibre networks, together creating a more fluid digestive environment where enzymes and substrates can interact efficiently.

Perhaps the most striking findings concerned bone health. The unsupplemented canola diet significantly impaired tibia development: bones were lighter and shorter, breaking strength dropped to about 3074 newtons compared with 4279 newtons in controls, and bone ash, calcium and phosphorus percentages all declined. These deficits trace directly back to phytate, which forms insoluble complexes with essential minerals and renders them unavailable for skeletal mineralisation. The protease-plus-phytase combination restored bone weight, length, strength and mineral chemistry to levels comparable with or exceeding the control group, with bone ash reaching 41.93 percent and calcium 15.57 percent. The authors note that improved protein digestibility from protease likely supported collagen matrix synthesis, providing the organic scaffold upon which calcium and phosphorus are deposited, while phytase liberated the minerals themselves.

The study’s conclusion carries real weight for feed formulators. Replacing soybean meal with 10 percent canola seed without enzyme support demonstrably harms growth, gut function and bone mineralisation in broilers. Yet the combined application of protease and phytase overcame these constraints, performing better than either enzyme alone. The synergy is mechanistically elegant: phytase dismantles the structural and chemical barriers that phytate erects around proteins and minerals, creating conditions in which protease can work more effectively, while protease maximises the value of the nutrients phytase releases. For producers weighing enzyme purchases against volatile protein prices, the message is that the two enzymes are genuinely complementary, and that canola seed, long treated as a second-tier ingredient, can approach soybean meal performance when the right enzymatic tools are applied.

Subject of Research: Effects of protease and phytase supplementation on growth performance, nutrient digestibility, gut health and bone mineralisation in broiler chickens fed canola seed diets

Article Title: Protease and Phytase Alleviate Digestive Limitations of Canola Seed in Broiler Chickens

Article References: Sheikh‐Nazari, R., Jafari‐Khorshidi, K., & Jafari, M. A. (2026). Protease and Phytase Alleviate Digestive Limitations of Canola Seed in Broiler Chickens. Veterinary Medicine and Science, 12(6), Article e71259. https://doi.org/10.1002/vms3.71259

Image Credits: AI Generated

DOI: 10.1002/vms3.71259

Keywords: broiler chickens, canola seed, phytase, protease, soybean meal replacement, nutrient digestibility, gut microbiota, intestinal morphology, tibia mineralisation, antinutritional factors, feed enzymes, poultry nutrition

The research team focused on a transcription factor called CCAAT/enhancer binding protein beta, or C/EBPβ, a DNA-binding protein known to regulate inflammatory and stress-response genes throughout the body. In the brain, C/EBPβ has previously attracted attention in neurodegeneration research, where elevated levels have been linked to the activation of asparagine endopeptidase, or AEP, a protease also known as legumain. AEP is an enzyme with a taste for particular asparagine residues, and when it becomes active it can cleave key neuronal proteins, destabilizing the delicate architecture of synapses. The Wuhan group hypothesized that this same transcription factor-to-protease circuit might be recruited by chronic stress in ways that erode synaptic homeostasis and precipitate the behavioral core of depression.

To test the idea, the researchers used a well-established rodent paradigm called chronic unpredictable mild stress, or CUMS, in which animals are exposed over weeks to a rotating series of low-grade stressors — altered light cycles, damp bedding, tilted cages, and other unpredictable annoyances. The approach reliably produces animals that show anhedonia, behavioral despair, and other measurable depression-like phenotypes, making it a standard preclinical proxy for the human disorder. When the team examined the hippocampus, a brain region indispensable for mood regulation and memory that is consistently implicated in stress-related psychiatric illness, they found that chronic stress activated C/EBPβ and drove up the expression of its downstream protease target, AEP. The pathway, in other words, is not a bystander in the stressed brain; it is switched on precisely where and when synaptic function begins to falter.

The causal experiments that followed form the evidentiary heart of the paper. When the researchers genetically knocked out C/EBPβ, the animals were substantially protected: the depression-like phenotypes induced by chronic unpredictable mild stress were alleviated, indicating that the transcription factor is required for stress to exert its full behavioral toll. A parallel experiment deleting AEP produced a similar protective effect, placing the protease downstream in the same causal chain. These loss-of-function results were complemented by gain-of-function studies that flipped the logic in the opposite direction. When the team overexpressed either C/EBPβ or AEP directly in the hippocampus of otherwise healthy animals, the depression-like phenotypes appeared without any external stress at all — a striking demonstration that elevating this single pathway is sufficient to reproduce the behavioral signature of chronic stress exposure.

Perhaps the most conclusive experiment was the epistasis test, a genetic technique used to establish the ordering of components within a pathway. If AEP truly acts downstream of C/EBPβ, then removing AEP should blunt the damage caused by forcing C/EBPβ into overdrive. That is exactly what the researchers observed: genetic deletion of AEP attenuated the detrimental effects induced by C/EBPβ overexpression. The result confirms a clean linear relationship — stress activates C/EBPβ, C/EBPβ elevates AEP, and AEP executes the synaptic sabotage that manifests as depression-like behavior. Taken together, the knockout, overexpression, and rescue experiments satisfy the classic criteria for causation in molecular medicine, elevating the C/EBPβ/AEP axis from correlation to mechanism.

Why does this matter for understanding depression itself? For decades, the dominant framework for stress-related mood disorders centered on monoamine neurotransmitters such as serotonin and norepinephrine, a view that produced widely prescribed antidepressants but left many patients without adequate relief. More recent scholarship has emphasized synaptic homeostasis — the brain’s ability to maintain the strength, number, and plasticity of connections between neurons — as a substrate of resilient mood regulation. Chronic stress is known to cause atrophy of dendritic spines and loss of synapses in the hippocampus and prefrontal cortex, and effective antidepressant treatments often restore synaptic connectivity. The new study supplies a concrete molecular route by which that synaptic erosion happens: a stress-activated transcription factor induces a protease that degrades the protein infrastructure of the synapse. In this framing, depression is not merely a chemical imbalance but a structural and enzymatic dismantling of the brain’s communication hardware.

The identification of AEP as the effector arm of the pathway is particularly intriguing from a therapeutic standpoint. Proteases are among the most druggable enzyme classes in biology, and inhibitors targeting legumain have already been explored in oncology and neurodegenerative disease contexts. The finding that AEP deletion protects animals from depression-like phenotypes, while its hippocampal overexpression is sufficient to induce them, suggests that a pharmacological inhibitor of AEP — or an intervention that dampens C/EBPβ activity upstream — could in principle interrupt the cascade before synapses are lost. The authors’ demonstration that removing AEP rescues the damage caused by C/EBPβ overexpression provides a direct proof of concept for that strategy, although the distance between mouse genetics and a human therapy remains considerable.

Important caveats temper the translation. The study relies on animal models whose fidelity to human depression, while well validated, is imperfect; a rodent’s immobility in a forced swim test or its indifference to sucrose is not the same as the richly subjective experience of human despair. The hippocampus is also only one node in the distributed circuitry of mood, and stress is known to act on the prefrontal cortex, amygdala, and neuroendocrine systems in parallel. C/EBPβ is a pleiotropic transcription factor with essential roles in immune function and metabolism, so systemic suppression would carry risks that targeted brain delivery might avoid. Nonetheless, the mechanistic clarity of the pathway — a defined transcriptional trigger, a defined enzymatic effector, and bidirectional genetic evidence — gives the field a sharper set of questions to pursue in human tissue, human genetics, and clinical cohorts.

The work also connects depression to a broader theme in modern neuroscience: the shared vulnerability pathways that cut across seemingly distinct brain diseases. AEP has been implicated in Alzheimer’s disease, where it cleaves tau and other proteins, and C/EBPβ activation has been documented in aging and neuroinflammatory states. The new findings raise the possibility that chronic stress co-opts an ancient damage-response program — one that normally helps cells cope with injury — and that its sustained activation in mood circuitry becomes pathological. This overlap may help explain epidemiological observations that chronic stress, depression, and neurodegenerative risk travel together, and it positions the C/EBPβ/AEP axis as a candidate convergence point where psychiatric and neurodegenerative research can inform each other.

For now, the immediate significance of the study lies in its demonstration that a single, manipulable molecular pathway can carry much of the weight of stress-induced synaptic impairment and depression-like behavior. By showing that the pathway is both necessary — its removal protects — and sufficient — its activation harms — the Wuhan team has converted a diffuse clinical problem into a defined set of molecular targets. As the authors and their colleagues at Wuhan University, supported by the National Natural Science Foundation of China and provincial funding programs, continue to dissect how AEP remodels synaptic proteins under stress, the prospect of interventions that preserve synaptic integrity in the face of chronic stress moves from speculation toward testable strategy. For the millions of people whose depression resists current treatments, that shift in the mechanistic landscape is reason for measured but genuine optimism.

Subject of Research: The role of the C/EBPβ/AEP molecular pathway in chronic stress-induced synaptic impairment and depression

Article Title: C/EBPβ/AEP pathway mediates synaptic impairments and depression-like phenotypes induced by chronic stress

Article References: Xiong, M., Xia, D., Yang, Y., Li, Y., Pan, L., Liu, C., Chen, Q., Zhang, Z., Xu, X., & Meng, L. (2026). C/EBPβ/AEP pathway mediates synaptic impairments and depression-like phenotypes induced by chronic stress. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06426-4

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06426-4

Keywords: depression, chronic stress, C/EBPβ, AEP, legumain, synapses, hippocampus, neuroinflammation, transcription factor, protease, mental health, preclinical models

Biofilms are structured communities of bacteria encased in a self-produced matrix of proteins, extracellular DNA, and polysaccharides. Within these fortresses, pathogens become dramatically more tolerant of antibiotics and immune attack, which is why biofilms complicate the treatment of cystic fibrosis lungs, chronic wounds, medical implants, and catheter-associated infections. Pseudomonas aeruginosa and Staphylococcus aureus are flagship biofilm builders, and both appear on global lists of antibiotic-resistant priority pathogens. An enzyme that can chew through the proteinaceous scaffolding of a biofilm, or disrupt the physiology of the cells inside it, therefore represents a genuinely different therapeutic strategy: rather than killing bacteria outright, it dismantles the architecture that makes them so hard to eradicate.

Serratiopeptidase, sometimes marketed as serrapeptase, is an extracellular protease naturally secreted by Serratia marcescens. It has been used for decades, particularly in Japan and India, as an anti-inflammatory and anti-edema agent, and earlier studies have hinted that it can affect Pseudomonas physiology and biofilm integrity. What has been missing is a rigorous, quantitative characterization of a purified preparation, since crude enzyme mixtures make it impossible to attribute activity to a single protein. The new study addressed this gap with a four-step purification pipeline: precipitation, dialysis, ion-exchange chromatography, and gel filtration chromatography, which together yielded a 15.91-fold increase in purity, sufficient for reliable biochemical and kinetic analysis.

With the purified enzyme in hand, the team determined its molecular weight to be approximately 47 kilodaltons, consistent with the serralysin-like metalloproteases produced by Serratia species. The enzyme displayed broad substrate specificity but showed its highest affinity toward casein, a milk protein commonly used as a benchmark substrate in protease assays. Activity peaked at pH 7 and 40 degrees Celsius, close to physiological conditions, and the enzyme proved remarkably durable under these optima, retaining 89.2 percent and 82.4 percent of its activity, respectively, after 60 minutes of incubation. That combination of neutral pH preference and moderate temperature optimum is exactly what one would want in a therapeutic protein intended to function inside the human body.

The kinetic analysis revealed an enzyme of impressive catalytic power. The Michaelis constant, Km, was 0.034 millimolar, equivalent to 842 micrograms per milliliter, indicating tight substrate binding, while the maximum velocity, Vmax, reached 738.2 units per milliliter. The turnover number, kcat, came in at 55.3 per second, meaning each enzyme molecule processes more than 55 substrate molecules every second. Dividing kcat by Km yields a catalytic efficiency of 1.64 × 10⁶ per molar per second, a figure that places this serratiopeptidase firmly in the category of highly efficient catalysts. For a protein being considered as a drug candidate, such numbers matter: an efficient enzyme can deliver biological effects at lower doses, reducing cost and potential side effects.

Equally informative was the enzyme’s response to chemical modulators. Metal ions including zinc, cobalt, barium, and manganese enhanced activity, as did the non-ionic detergent Tween-20 and the reducing agent beta-mercaptoethanol. Conversely, EDTA, a chelator that strips away metal cofactors, and PMSF, a classic serine protease inhibitor, both shut the enzyme down. This dual sensitivity is diagnostic: it confirms that the SP6 enzyme is a serine-metalloprotease, a hybrid classification consistent with the serralysin family, in which a catalytic serine operates within a metal-dependent active site. Knowing this helps predict how the enzyme will behave in complex biological environments and informs strategies for stabilizing it in formulation.

Perhaps the most clinically relevant findings concern stability and resistance to degradation. The enzyme retained 61.31 percent of its activity after 60 days of storage at 4 degrees Celsius, a refrigerated shelf life that simplifies handling and distribution. More strikingly, it resisted digestion by trypsin and by human serum, with in vitro half-lives of 4 and 5 hours, respectively. Therapeutic proteins typically face rapid destruction by circulating proteases and serum components, so a bacterial enzyme that survives hours in serum-like conditions is unusual and valuable. The authors note that extending the half-lives of therapeutic proteins is a major focus of drug development, and intrinsic resistance to proteolysis gives this enzyme a head start.

The anti-biofilm experiments delivered the study’s headline result. Against Pseudomonas aeruginosa MTCC 2453, serratiopeptidase achieved a maximum biofilm inhibition of 41.65 percent at a concentration of 200 micrograms per milliliter, with an IC50 of 56.92 plus or minus 8 micrograms per milliliter. Against Staphylococcus aureus MTCC 1430, the maximum inhibition was 21.87 percent at the same dose, with an IC50 of 124.6 plus or minus 8 micrograms per milliliter. The authors are careful to define these IC50 values relative to the normalized response range, meaning they correspond to 50 percent of the observed inhibitory effect rather than absolute halving of biofilm mass, a methodological honesty that strengthens the credibility of the data. The stronger effect against Pseudomonas aligns with earlier reports that serratiopeptidase alters the physiology of Pseudomonas isolates from cystic fibrosis patients and disrupts Pseudomonas biofilms and functional amyloids.

What makes these numbers exciting is not that the enzyme obliterates biofilms on its own, but that partial disruption is often enough to restore the vulnerability of embedded bacteria. Anti-biofilm agents are increasingly viewed as adjuncts: by loosening or thinning the matrix, they allow antibiotics and immune cells to reach cells that would otherwise remain sheltered. A 41.65 percent reduction in Pseudomonas biofilm formation, achieved by a single enzyme at a modest concentration, could meaningfully amplify the efficacy of co-administered antimicrobials. The enzyme’s activity at neutral pH and 40 degrees Celsius, its serum stability, and its resistance to trypsin all support the plausibility of such combination approaches.

Significant hurdles remain before serratiopeptidase reaches the clinic as an anti-biofilm drug. The current work used a partially purified preparation, and further purification, scale-up of production, formulation studies, toxicity testing, and ultimately animal and clinical trials will be required. The enzyme’s origin from Serratia marcescens, an opportunistic pathogen itself, raises production and safety questions that recombinant expression systems, which have already been used to produce serratiopeptidase in cell-free platforms, could help resolve. Nevertheless, by systematically documenting the enzyme’s molecular weight, kinetics, inhibitor profile, storage stability, serum resistance, and anti-biofilm potency, Kumar and Bhattacharya have transformed a supplement-shelf enzyme into a well-characterized candidate for rational development. As antibiotic resistance continues to erode the effectiveness of conventional drugs, enzymes that dismantle bacterial fortresses rather than merely poisoning the bacteria inside them may prove to be one of the most important weapons in the next generation of anti-infective therapy.

Subject of Research: Biochemical characterization and anti-biofilm activity of serratiopeptidase from Serratia marcescens SP6

Article Title: Elucidation of the biochemical properties of a partially purified Serratia marcescens SP6 serratiopeptidase with anti-biofilm efficacy

Article References: Kumar, S., & Bhattacharya, S. (2026). Elucidation of the biochemical properties of a partially purified Serratia marcescens SP6 serratiopeptidase with anti-biofilm efficacy. 3 Biotech, 16(10), Article 433. https://doi.org/10.1007/s13205-026-05063-9

Image Credits: AI Generated

DOI: 10.1007/s13205-026-05063-9

Keywords: serratiopeptidase, Serratia marcescens, biofilm, Pseudomonas aeruginosa, Staphylococcus aureus, protease, enzyme kinetics, antibiotic resistance, metalloprotease, anti-biofilm therapy, protein purification, therapeutic enzymes